Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.
Transplantation of immunocompetent cells present within allogeneic bone marrow has been associated with the elimination of residual host leukemia, both in animal tumor models and in patients receiving marrow transplants for leukemia. This observation has been called the "graft-versus-leukemia effect." We have attempted to study this phenomenon in vitro by characterizing the cytolytic response of T cells from normal donors after in vitro activation with allogeneic leukemic cells. As expected, most T cells that react against an allogeneic patient's leukemic cells recognize their foreign HLA antigens and lyse the patient's nonleukemic remission lymphoid cells. In addition, we have shown that a small fraction of the T cells recognize and lyse foreign leukemic targets without lysis of nonmalignant remission targets from the same leukemic patient. These T cells have been isolated and characterized as CD3+, CD4+ cells expressing the alpha/beta T cell receptor (TCR). Their lysis appears to reflect specific antigen recognition mediated via the CD3-TCR complex and interactions involving the CD4 receptor. Some of these "leukemic specific" T cell lines, which are restricted by HLA class II molecules, can also lyse occasional nonleukemic cells from certain unrelated donors. This recognition appears to involve crossreactive determinants shared by the leukemic cells and the unrelated allogeneic nonleukemic cells. These specific interactions may represent an in vitro model of the graft-versus-leukemia effect.
Department of Human Oncology, University of Wisconsin, Madison.
J A
JA
Sosman
K R
KR
Oettel
S D
SD
Smith
J A
JA
Hank
P
P
Fisch
P M
PM
Sondel
D000941:Antigens / Q000276:immunology*; D001853:Bone Marrow / Q000276:immunology / Q000473:pathology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000473:pathology; D002455:Cell Division; D002460:Cell Line; D003429:Cross Reactions / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D006087:Graft vs Host Reaction; D006681:HLA-D Antigens / Q000276:immunology; D006682:HLA-DP Antigens / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology / Q000502:physiology; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000473:pathology*; D008285:Major Histocompatibility Complex / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology / Q000648:ultrastructure; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000941:Antigens; D000939:Epitopes; D006681:HLA-D Antigens; D006682:HLA-DP Antigens; D000949:Histocompatibility Antigens Class II; D011948:Receptors, Antigen, T-Cell